ALDX
Aldeyra TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
ALDX Profile
Aldeyra Therapeutics, Inc.
A biotechnology company developing novel therapies for immune-mediated diseases
131 Hartwell Avenue, Suite 320, Lexington, MA 02421
--
Aldeyra Therapeutics, Inc., was incorporated in Delaware on August 13, 2004 as Neuron Systems, Inc. The company is a biotechnology company focused on developing products to treat immune-mediated, inflammatory, orphan, and diseases believed to be associated with a naturally toxic chemical species called free aldehydes. Aldeyra Therapeutics is developing next-generation drugs to improve the lives of patients with immune-mediated diseases. Aldeyra's lead product candidate, reproxalap, is a first-in-class treatment for late-developed forms of dry eye and ocular inflammation. Aldeyra is also developing product candidates for autoimmune diseases, post-transplant lymphoproliferative diseases, retinal inflammation, metabolic diseases and cancer. None of Aldeyra's product candidates are approved in the United States.
